Versant-backed Bright Peak sets a date to bring its IL-2 into the clinic — but all eyes are on an IPO after latest mega-round drops

Just under a year after securing its first venture round, a Versant-backed startup has pulled in a massive Series B haul to create designer cytokines —and it seems as though CEO Fredrik Wiklund is keeping the S-1 paperwork in his back pocket.

Bright Peak Therapeutics unveiled a $107 million Series B round on Thursday morning, led by RA Capital with some help from Versant, Fidelity Management & Research Company, Invus, Qatar Investment Authority, BlackRock, Alexandria Venture Investments and an undisclosed investor.